Overview

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Status:
Withdrawn
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether treatment of E7777 in combination with CHOP has superior efficacy compared with CHOP alone in improving complete response rate (CRR) in first line treatment of subjects with Peripheral T-cell Lymphoma (PTCL).
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Inc.